Covalon Technologies Ltd. (COV.V)
CAD 2.25
(-0.44%)
CAD 2.25
(-0.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.36 Million CAD | 13.55% |
| 2022 | 16.63 Million CAD | 87.81% |
| 2021 | 8.85 Million CAD | -52.32% |
| 2020 | 18.57 Million CAD | -38.22% |
| 2019 | 30.07 Million CAD | 66.62% |
| 2018 | 18.04 Million CAD | -6.01% |
| 2017 | 19.2 Million CAD | 169.81% |
| 2016 | 7.11 Million CAD | 29.05% |
| 2015 | 5.51 Million CAD | 33.21% |
| 2014 | 4.13 Million CAD | 33.7% |
| 2013 | 3.09 Million CAD | -39.67% |
| 2012 | 5.13 Million CAD | 4.24% |
| 2011 | 4.92 Million CAD | 43.96% |
| 2010 | 3.42 Million CAD | -42.69% |
| 2009 | 5.96 Million CAD | 10.77% |
| 2008 | 5.38 Million CAD | 40.34% |
| 2007 | 3.83 Million CAD | 41.07% |
| 2006 | 2.72 Million CAD | 47.88% |
| 2005 | 1.84 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.13 Million CAD | -28.18% |
| 2024 Q2 | 3.63 Million CAD | -11.96% |
| 2024 Q3 | 3.76 Million CAD | 49.29% |
| 2023 Q1 | 4.05 Million CAD | -24.39% |
| 2023 Q4 | 5.75 Million CAD | 37.25% |
| 2023 Q2 | 4.89 Million CAD | 20.81% |
| 2023 FY | 18.89 Million CAD | 13.55% |
| 2023 Q3 | 4.19 Million CAD | -14.34% |
| 2022 Q4 | 5.35 Million CAD | 43.82% |
| 2022 Q3 | 3.72 Million CAD | -10.59% |
| 2022 FY | 16.63 Million CAD | 87.81% |
| 2022 Q1 | 3.38 Million CAD | 269.43% |
| 2022 Q2 | 4.16 Million CAD | 22.98% |
| 2021 Q4 | -1.99 Million CAD | -151.07% |
| 2021 Q1 | 3.83 Million CAD | 1.2% |
| 2021 FY | 8.85 Million CAD | -52.32% |
| 2021 Q2 | 3.1 Million CAD | -19.16% |
| 2021 Q3 | 3.91 Million CAD | 26.16% |
| 2020 Q4 | 3.79 Million CAD | 50.23% |
| 2020 Q3 | 2.52 Million CAD | -61.0% |
| 2020 FY | 18.57 Million CAD | -38.22% |
| 2020 Q2 | 6.47 Million CAD | 11.93% |
| 2020 Q1 | 5.78 Million CAD | -19.87% |
| 2019 Q2 | 9.35 Million CAD | 51.55% |
| 2019 FY | 30.07 Million CAD | 66.62% |
| 2019 Q1 | 6.17 Million CAD | 25.8% |
| 2019 Q3 | 7.31 Million CAD | -21.81% |
| 2019 Q4 | 7.21 Million CAD | -1.35% |
| 2018 Q2 | 4.81 Million CAD | 19.87% |
| 2018 Q3 | 4.3 Million CAD | -10.5% |
| 2018 FY | 18.04 Million CAD | -6.01% |
| 2018 Q1 | 4.01 Million CAD | -42.52% |
| 2018 Q4 | 4.9 Million CAD | 13.94% |
| 2017 Q4 | 6.98 Million CAD | 70.47% |
| 2017 FY | 19.2 Million CAD | 169.81% |
| 2017 Q1 | 3.91 Million CAD | 55.42% |
| 2017 Q2 | 4.22 Million CAD | 7.88% |
| 2017 Q3 | 4.09 Million CAD | -3.05% |
| 2016 Q1 | 1.29 Million CAD | -34.78% |
| 2016 Q4 | 2.52 Million CAD | 40.61% |
| 2016 Q3 | 1.79 Million CAD | 19.4% |
| 2016 Q2 | 1.5 Million CAD | 15.56% |
| 2016 FY | 7.11 Million CAD | 29.05% |
| 2015 FY | 5.51 Million CAD | 33.21% |
| 2015 Q3 | 1.29 Million CAD | 12.0% |
| 2015 Q4 | 1.99 Million CAD | 53.46% |
| 2015 Q2 | 1.15 Million CAD | 9.02% |
| 2015 Q1 | 1.06 Million CAD | -17.55% |
| 2014 Q3 | 920.42 Thousand CAD | -1.68% |
| 2014 Q4 | 1.28 Million CAD | 40.12% |
| 2014 FY | 4.13 Million CAD | 33.7% |
| 2014 Q1 | 993.41 Thousand CAD | 67.24% |
| 2014 Q2 | 936.14 Thousand CAD | -5.76% |
| 2013 Q2 | 789.33 Thousand CAD | -22.52% |
| 2013 Q3 | 694.14 Thousand CAD | -12.06% |
| 2013 FY | 3.09 Million CAD | -39.67% |
| 2013 Q4 | 594.01 Thousand CAD | -14.42% |
| 2013 Q1 | 1.01 Million CAD | -34.81% |
| 2012 Q3 | 1.3 Million CAD | 16.86% |
| 2012 Q4 | 1.56 Million CAD | 19.85% |
| 2012 FY | 5.13 Million CAD | 4.24% |
| 2012 Q1 | 1.14 Million CAD | -25.2% |
| 2012 Q2 | 1.11 Million CAD | -2.97% |
| 2011 Q2 | 1.13 Million CAD | 20.39% |
| 2011 Q1 | 946.57 Thousand CAD | -21.54% |
| 2011 FY | 4.92 Million CAD | 43.96% |
| 2011 Q4 | 1.53 Million CAD | 18.26% |
| 2011 Q3 | 1.3 Million CAD | 14.09% |
| 2010 Q1 | 781.87 Thousand CAD | -67.4% |
| 2010 Q4 | 1.2 Million CAD | 61.59% |
| 2010 Q3 | 746.59 Thousand CAD | 8.93% |
| 2010 Q2 | 685.4 Thousand CAD | -12.34% |
| 2010 FY | 3.42 Million CAD | -42.69% |
| 2009 FY | 5.96 Million CAD | 10.77% |
| 2009 Q1 | 1.15 Million CAD | -54.39% |
| 2009 Q3 | 950.44 Thousand CAD | -35.05% |
| 2009 Q2 | 1.46 Million CAD | 26.52% |
| 2009 Q4 | 2.39 Million CAD | 152.31% |
| 2008 Q1 | 1.25 Million CAD | -6.28% |
| 2008 FY | 5.38 Million CAD | 40.34% |
| 2008 Q3 | 763.87 Thousand CAD | -47.01% |
| 2008 Q2 | 1.44 Million CAD | 14.41% |
| 2008 Q4 | 2.53 Million CAD | 231.95% |
| 2007 Q1 | 591.15 Thousand CAD | -33.33% |
| 2007 Q3 | 1.12 Million CAD | 44.88% |
| 2007 Q4 | 1.34 Million CAD | 19.35% |
| 2007 Q2 | 777.46 Thousand CAD | 31.52% |
| 2007 FY | 3.83 Million CAD | 41.07% |
| 2006 Q3 | 690.19 Thousand CAD | 10.63% |
| 2006 FY | 2.72 Million CAD | 47.88% |
| 2006 Q4 | 886.75 Thousand CAD | 28.48% |
| 2006 Q1 | 520.82 Thousand CAD | -45.9% |
| 2006 Q2 | 623.88 Thousand CAD | 19.79% |
| 2005 Q4 | 962.62 Thousand CAD | 173.11% |
| 2005 Q2 | 346.28 Thousand CAD | 93.39% |
| 2005 FY | 1.84 Million CAD | 0.0% |
| 2005 Q1 | 179.06 Thousand CAD | 0.0% |
| 2005 Q3 | 352.46 Thousand CAD | 1.78% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arch Biopartners Inc. | 3.22 Million CAD | -345.167% |
| Hemostemix Inc. | 2.15 Million CAD | -565.903% |
| Universal Ibogaine Inc. | 5.81 Million CAD | -146.892% |
| Kane Biotech Inc. | 3.46 Million CAD | -314.261% |
| MedMira Inc. | 1.5 Million CAD | -851.489% |
| Marvel Biosciences Corp. | 2.31 Million CAD | -519.33% |
| NervGen Pharma Corp. | 17.77 Million CAD | 19.21% |
| XORTX Therapeutics Inc. | 6.38 Million CAD | -125.041% |